13.04.2012 - Finland is the last Nordic country which has not yet decided to start a nationwide bioeconomy programme. Calls for such an strategy are becoming louder.
Helsinki – Denmark has already implemented a national bioeconomy strategy, investing €1.8bn by 2015. At the end of March, Norway and Sweden announced at the "Bioeconomy in Action" conference that they would also start countrywide efforts. Norway intends to spend as much as €300m in total. Demands for Finland not to fall behind are becoming more pressing. Erkki KM Leppävuori, President and CEO of the VTT Technical Research Centre of Finland, said during a conference on April 12, "Finland should create a national bioeconomy strategy as soon as possible". According to Leppävuori, bioeconomy has all the prerequisites for creating a radical increase in the value of exports and for developing into a new pillar of support for wellbeing in Finland. "This will require the making of choices, the taking of risks, and the development and marketing of bioeconomy-based technologies", he added. Finland’s forest industry especially might profit from such a move. According to expert assessment, by 2020 new technological solutions and diversification could raise Finland's production by €6bn (equal to an increase of 22% compared to the 2010 level). Current operations could be expanded into the production of composites, biofuels and biochemicals, and into service businesses. Leppävuori already has a suggestion for facilitating the necessary changes, "The renewal of Finland’s business sector can be expedited by forming a voluntary partnership network – the Finnish Institute of Technology and Innovation (FIT). Research programs in the network could be opened up to each other and large-scale multidisciplinary projects initiated in applied research." Leppävuori added, "This is also a question of effective utilization of Finland’s limited research resources."
26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.
24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.
23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.
19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.
17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).
15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).
09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.
08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.
FILTRODISC™ BIO SD is a filtration system which removes particles (e.g. cells, bacteria, yeast), impurities (e.g. HCP, DNA) and other turbid matter from process liquids (e.g. fermentation broths). more